Physician profile
Amelia Young
NPI 1144405903
$10,423.70
in general payments reported to CMS, 2019-2025
32 companies · $1,048 in 2025
The $1,048 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,851 · 2020: $1,245 · 2021: $413 · 2022: $1,435 · 2023: $1,134 · 2024: $1,297 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.05 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,227.62 | 2019-2025 | Nc Trek Neo, Pressurewire, Xience Skypoint |
| Astrazeneca Pharmaceuticals Lp | $1,221.36 | 2019-2024 | Brilinta, Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $959.24 | 2022-2025 | |
| Amgen INC. | $848.65 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $772.51 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $680.68 | 2019-2025 | Jardiance |
| Medtronic, INC. | $588.23 | 2022-2025 | Micra, Advisa Dr Mri Surescan, Linq II |
| Pfizer INC. | $442.36 | 2019-2025 | |
| Amarin Pharma, INC. | $435.27 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $182.51 | 2020-2025 | Camzyos, Eliquis |
| Glaxosmithkline, LLC. | $155.84 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $131.53 | 2020-2024 | Xarelto |
| Intuitive Surgical, INC. | $88.15 | 2024 | |
| Sunovion Pharmaceuticals INC. | $71.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $70.74 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $68.02 | 2020-2023 | Lifevest |
| Cardiva Medical, INC. | $65.53 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Esperion Therapeutics, INC. | $58.69 | 2020-2023 | Nexletol |
| Philips North America LLC | $50.36 | 2019 | |
| Corcept Therapeutics | $49.93 | 2025 | Korlym |
| Boston Scientific Corporation | $48.73 | 2024-2025 | Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack |
| Gilead Sciences, INC. | $28.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.53 | 2019 | |
| Cordis US Corp. | $23.44 | 2024 | Mynxgrip |
| Bausch & Lomb Americas INC. | $20.46 | 2025 | Miebo |
| Kiniksa Pharmaceuticals, Ltd. | $20.08 | 2021 | |
| Cardiovascular Systems INC. | $19.69 | 2022 | |
| Edwards Lifesciences Corporation | $16.99 | 2025 | |
| Merck Sharp & Dohme LLC | $14.18 | 2022 | |
| B. Braun Interventional Systems INC. | $14.06 | 2025 | Na |
| Kowa Pharmaceuticals America, INC. | $12.47 | 2019 | |
| Medtronic Vascular, INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.